Assessment of oritavancin serum protein binding across species

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3481-3483

  Arhin, Francis F ^a   Belley, Adam ^a   McKay, Geoffrey ^a,b   Beaulieu, Sylvain ^a   Sarmiento, Ingrid ^a   Parr Jr , Thomas R ^a   Moeck, Gregory ^a  

^a The Medicines Company   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; DAPTOMYCIN; ORITAVANCIN;

ARTICLE; BACTERIAL GROWTH; DRUG ADSORPTION; DRUG EXPOSURE; DRUG PROTEIN BINDING; HUMAN; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD PROTEINS; CEPHALOSPORINS; DAPTOMYCIN; DOGS; GLYCOPEPTIDES; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; RATS; SPECIES SPECIFICITY; STAPHYLOCOCCUS AUREUS;

EID: 77955372998     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00271-10     Document Type: Article

References (23)

1. Arhin, F. F., I. Sarmiento, A. Belley, G. A. McKay, D. C. Draghi, P. Grover, D. Sahm, T. R. Parr, Jr., and G. Moeck. 2008. Effect of polysorbate-80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob. Agents Chemother. 52:1597-1603.
2. Arhin, F. F., I. Sarmiento, T. R. Parr, Jr., and G. Moeck. 2008. Binding of oritavancin to surfaces impacts choice of vessels for oritavancin in vitro assays, abstr. B1. Abstr. 58th Annu. Meet. Can. Soc. Microbiol. Canadian Society for Microbiology, Ottawa, Canada.
3. Bailey, E. M., M. J. Rybak, and G. W. Kaatz. 1991. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob. Agents Chemother. 35:1089-1092.
4. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th edition. Approved standard M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing, 19th information supplement. M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Crandon, J., and D. P. Nicolau. 2008. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens. Future Microbiol. 3:251-263.
7. Kunin, C. M., W. A. Craig, M. Kornguth, and R. Monson. 1973. Influence of binding on the pharmacologic activity of antibiotics. Ann. N. Y. Acad. Sci. 226:214-224.
8. Lee, B. L., M. Sachdeva, and H. F. Chambers. 1991. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. 35:2505-2508.
9. Leggett, J. E., and W. A. Craig. 1989. Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli. Antimicrob. Agents Chemother. 33:35-40.
10. MacGowan, A., and K. Bowker. 2004. In vitro studies on the impact of human serum on the antibacterial effect of faropenem. J. Chemother. 16:23-29.
11. McKay, G. A., S. Beaulieu, F. F. Arhin, A. Belley, I. Sarmiento, T. R. Parr, Jr., and G. Moeck. 2009. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J. Antimicrob. Chemother. 63:1191-1199.
12. McKay, G. A., S. Beaulieu, D. Lehoux, T. R. Parr, Jr., and G. Moeck. 2009. Evaluation of oritavancin activity in vitro in the presence of human and mouse serum, abstr. P1854. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
13. Mouton, J. W., P. G. Ambrose, G. Kahlmeter, M. Wikler, and W. A. Craig. 2007. Applying pharmacodynamics for susceptibility breakpoint selection and susceptibility testing, p. 21-44. In C. H. Nightingale, P. G. Ambrose, G. L. Drusano, and T. Murakawa (ed.), Antimicrobial pharmacodynamics in theory and clinical practice. Informa Healthcare, New York, NY.
14. Ndieyira, J. W., M. Watari, A. D. Barrera, D. Zhou, M. Vögtli, M. Batchelor, M. A. Cooper, T. Strunz, M. A. Horton, C. Abell, T. Rayment, G. Aeppli, and R. A. McKendry. 2008. Nanomechanical detection of antibiotic-mucopeptide binding in a model for superbug drug resistance. Nat. Nanotechnol. 3:691-696.
15. Popick, A. C., W. G. Crouthamel, and I. Bekersky. 1987. Plasma protein binding of ceftriaxone. Xenobiotica 17:1139-1145.
16. Rowe, P. A., and T. J. Brown. 2001. In vitro protein binding of [14C]oritavancin in human plasma at 1, 10 and 91 μg/mL employing a dextran coated charcoal adsorption method, abstr. A2193. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
17. Schmidt, S., D. Gonzalez, and H. Derendorf. 2010. Significance of protein binding in pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 99:1107-1122.
18. Schmidt, S., K. Röck, M. Sahre, O. Burkhardt, M. Brunner, M. T. Lobmeyer, and H. Derendorf. 2008. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob. Agents Chemother. 52: 3994-4000.
19. Shaw, J. P., J. McCullough, and S. Jaw Tsai. 2008. Protein binding of [14C]-telavancin in plasma and human skin blister fluid, abstr. A-1824. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
20. Tsuji, B. T., J. B. Bulitta, P. A. Kelchlin, P. N. Holden, and A. Forrest. 2009. Determining the active fraction of daptomycin against MRSA by evaluating bactericidal activity in the presence of protein and pharmacodynamic (PD) modeling, abstr A1-1270/1. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
21. Tsuji, B. T., S. N. Leonard, P. R. Rhomberg, R. N. Jones, and M. J. Rybak. 2008. Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagn. Microbiol. Infect. Dis. 60:441-444.
22. Yuk, J. H., C. H. Nightingale, and R. Quintiliani. 1989. Clinical pharmacokinetics of ceftriaxone. Clin. Pharmacokinet. 17:223-235.
23. Zhanel, G. G., I. D. Kirkpatrick, D. J. Hoban, A. M. Kabani, and J. A. Karlowsky. 1998. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2427-2430.